Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000260119

Medchemexpress LLC 3-[1-[(3S)-1-prop-2-enoylpyrrolidin-3-yl]oxyisoquinolin-3-yl]-1,4-dihydro-1,2,4-triazol-5-one | 1627603-21-7 | 99.9% | C18H17N5O3 | 10MG
SDP

Supplier:  Medchemexpress LLC HY13287910MG

Encompass_Preferred

TAK-020 is a covalent Bruton's tyrosine kinase (BTK) inhibitor developed by Takeda and advanced as a clinical candidate for hematologic malignancies and autoimmune diseases. It irreversibly binds Cys481 in BTK's ATP-binding site and is provided by research suppliers as a characterized small-molecule reagent (CAS 1627603-21-7).

  • Covalent inhibitor that targets Cys481 in BTK.
  • Selective BTK inhibition supported by preclinical and clinical data.
  • Well-characterized small molecule with published analytical reports.
  • Available from vendors in mg-scale quantities for research use.
  • Typically supplied as high-purity material for in vitro and in vivo studies.

Catalog No. 50-002-60119


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.